BRD4 inhibitor GNE987 exerts anti-cancer effects in Osteosarcoma
GNE987 is a newly developed von Hippel-Lindau tumor suppressor (VHL)-based pan-BET-targeting PROTAC, which can bind to the target proteins (BET proteins, including BRD2, BRD3, and BRD4) and recruit them to the ubiquitin/proteasome system for selective degradation. In the our study, ChIP-Seq analysis was performed to explore the effect of GNE987 on osteosarcoma cells. Overall design: Genome binding/occupancy profiling of histone H3K27ac in osteosarcoma cells were generated by ChIP-Seq using DNBSEQ-G400